Comparative efficacy and safety of antibacterial regimens for severe Stenotrophomonas maltophilia infections: A systematic review and network meta-analysis.

Int J Infect DisAug 4, 2026 (epub)
Clinical ResearchInfectious Diseases

Suyu Gao, Yun Lu, Qi Qiao

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the efficacy and survival benefits of various antimicrobial regimens for treating multidrug-resistant Stenotrophomonas maltophilia infections. The analysis included 15 cohorts and found that levofloxacin significantly improved survival compared to TMP-SMX (OR = 2.01, 95%CI 1.16-3.47, P = 0.012), while tigecycline showed the highest clinical response but no survival benefit.

Key findings

  • Levofloxacin improved survival compared to TMP-SMX with an OR of 2.01.
  • Tigecycline had the highest clinical response with an OR of 4.97.
  • Levofloxacin ranked first for mortality reduction with a SUCRA of 91.3%.
  • Tigecycline ranked first for clinical efficacy with a SUCRA of 91.3%.

Why it matters

Understanding the comparative efficacy of antimicrobial regimens is crucial for optimizing treatment strategies in patients with severe Stenotrophomonas maltophilia infections, particularly in critically ill populations where survival is a primary concern.

Source

PubMed · PMID 42551584

Published in Int J Infect Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.